Collins Stewart Reiterates a 'Buy' on Impax Laboratories (IPXL); Our Top Pick for 2012
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Price: $18.30 --0%
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Collins Stewart reiterates a 'Buy' on Impax Laboratories (NASDAQ: IPXL) price target of $30.00.
Collins analyst says, "We are reiterating our rating and price target for IPXL shares post the announcement that it has initiated a Phase IIb trial with IPX159 for the treatment of moderate to severe Restless Legs Syndrome (RLS). IPXL expects to present this data by mid-2013. If approved IPX159 would be entitled to 5 years of NCE (new chemical entity) marketing exclusivity. IPXL filed a US patent for the drug about a year ago which is still pending approval. IPX159 is approved in the EU for another indication. IPXL has worldwide rights to IPX159 for the treatment of RLS. According to IPXL, approximately 20MM to 25MM people have RLS in the US, and this is an $800MM market opportunity. The company estimates that IPX159 could have peak sales of over $100MM to $200MM annually."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $18.88 yesterday.
Collins analyst says, "We are reiterating our rating and price target for IPXL shares post the announcement that it has initiated a Phase IIb trial with IPX159 for the treatment of moderate to severe Restless Legs Syndrome (RLS). IPXL expects to present this data by mid-2013. If approved IPX159 would be entitled to 5 years of NCE (new chemical entity) marketing exclusivity. IPXL filed a US patent for the drug about a year ago which is still pending approval. IPX159 is approved in the EU for another indication. IPXL has worldwide rights to IPX159 for the treatment of RLS. According to IPXL, approximately 20MM to 25MM people have RLS in the US, and this is an $800MM market opportunity. The company estimates that IPX159 could have peak sales of over $100MM to $200MM annually."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $18.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
- SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Collins StewartSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
